Unlocking Value: 8 Crucial Facts About the Sudeep Pharma IPO You Can’t Miss!
Sudeep Pharma IPO: If you’re scouting for fresh IPO plays in India’s speciality ingredients world, the upcoming Sudeep Pharma IPO is worth a closer look. Riding on strong growth in the excipients and speciality-ingredients business, this Gujarat-based firm is set to hit the bourses with its maiden issue.
Below is a detailed breakdown—tailored for the Indian investor—covering the IPO’s key metrics, pros and cons, peer context, promoter holdings, financials, and FAQs.
What exactly is Sudeep Pharma and what is the Sudeep Pharma IPO about?
Sudeep Pharma is a technology-driven manufacturer of excipients and speciality ingredients servicing the pharmaceutical, food and nutrition industries. The company filed its DRHP with the Securities and Exchange Board of India (SEBI) earlier in 2025.
The IPO is a book-built issue comprising a fresh issue plus an Offer for Sale (OFS). The fresh issue will help Sudeep Pharma fund manufacturing expansion; the OFS gives existing shareholders an exit/liquidity option.
When does the Sudeep Pharma IPO open, what is the price band, lot size and issue size?
| Metric | Details |
|---|---|
| IPO Open Date | 21 November 2025 |
| IPO Close Date | 25 November 2025 |
| Price Band | ₹ 563 to ₹ 593 per equity share |
| Minimum Lot Size | 25 shares |
| Total Issue Size | ~₹ 895 crore (Fresh: ~₹ 95 crore + OFS: ~₹ 800 crore) |
| Listing Date (Tentative) | 28 November 2025 |
What are the key objects / uses of the Sudeep Pharma IPO ?
The company plans to deploy the fresh issue proceeds primarily for:
- Capital expenditure to procure machinery for its Nandesari Facility I.
- General corporate purposes (working capital, R&D, tech infrastructure).
What are Sudeep Pharma’s strengths & weaknesses?
Strengths
- Long-standing experience (incorporated 1989) in niche excipients & speciality ingredient business.
- Global customer base: over 1,100 customers and presence across US, Europe, Asia-Pacific.
- High-entry barrier manufacturing (encapsulation, spray drying, granulation) and accredited facilities.
- Positive growth in revenue and profitability in recent years.
Weaknesses / Risks
- Customer concentration risk: top customers form a large portion of revenue.
- Regional concentration: major manufacturing is located in Gujarat, exposing it to regional disruptions.
- Regulatory/compliance risk in highly regulated pharmaceutical/ingredient space.
- High portion of issue as OFS (≈ 89%) limits fresh capital infusion relative to total size.
Who are the promoters & what is the shareholding?
Promoters include:
- Sujit Jaysukh Bhayani (Founder-MD)
- Shanil Bhayani, Avani Bhayani, Sujeet Jaysukh Bhayani HUF, Bhayani Family Trust and Riva Resources Pvt Ltd.
Pre-issue promoter shareholding is ~89.37% of paid-up capital.
Promoter holding post-issue is projected to fall to ~76.15% (depending on allotment).
What are the financials for the last three years & key ratios?
Financial Snapshot (₹ in crore)
| Fiscal Year | Revenue from Operations | Profit After Tax (PAT) |
|---|---|---|
| FY 23 (ended Mar-23) | ₹ 428.74 cr | ₹ 62.32 cr |
| FY 24 (ended Mar-24) | ₹ 459.28 cr | ₹ 133.19 cr |
| FY 25 (ended Mar-25) | ₹ 511.33 cr | ₹ 138.69 cr |
Key Financial Ratios
| Ratio | FY 23 | FY 24 | FY 25 |
|---|---|---|---|
| EBITDA Margin | ~33.29% | ~40.88% | ~39.70% |
| PAT Margin | ~14.54% | ~27.63% | ~27.63% or slightly higher |
| Debt-to-Equity | ~0.37x | ~0.21x | ~0.27x |
| ROE | ~52.74% in FY 23 | ~27.88% in FY 24 | Data for FY 25 not fully disclosed |
How does peer comparison stack up?
According to the RHP, Sudeep Pharma claims that there are no exact listed peer companies in India operating at the same scale in the excipients and speciality ingredients niche.
However, for broad context, comparison with listed pharma companies:
| Company | PE | Comments |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ~91x In | Large-cap generics/innovator mix |
| Divis Laboratories Ltd. | ~68x | Specialty APIs/chemicals |
| Sudeep Pharma (at upper band) | ~46x (estimated) | Niche excipients & speciality ingredients |
Given the high barrier niche and export exposure, Sudeep Pharma’s valuation appears mid-to-high relative to peers.
What are the likely investment takeaways?
Why consider it:
- Entry into a specialty ingredient business with high technical barriers and global client base.
- Strong growth witnessed in recent years and disciplined profitability metrics.
- Fresh capex plan may drive expansion and margin improvement.
Things to watch:
- Majority of opportunity is in OFS—investors may not get full fresh growth capital benefit.
- Concentrated customer/supplier base and export/regulatory risk remain key.
- Market sentiment and pricing will matter—the issue is priced in moderately high valuation zone.
Conclusion
In a nutshell, Sudeep Pharma IPO provides access into a niche yet globally-oriented ingredient manufacturing business expanding its footprint. For investors with a long-term horizon and comfort with the science-driven manufacturing sector, this may be a compelling play—provided the pricing is judged fairly and risks are understood carefully.
Sudeep Pharma IPO FAQs (Frequently Asked Questions)
1. What is the minimum amount I need to invest?
The retail lot size is 25 shares at the price band of ₹ 563-593, so minimum investment is approx ₹ 14,075 (25 × ₹ 563).
2. Who are the lead managers?
The book-running lead managers are ICICI Securities Ltd. and IIFL Capital Services Ltd.
3. Which stock exchanges will Sudeep Pharma IPO be listed on?
The shares will list on both the National Stock Exchange of India (NSE) and BSE Ltd.
4. What is the price band and how is it fixed?
The price band is ₹ 563-593 per share. It is fixed by the company in consultation with lead managers before the issue opens
5. What is the lot size and retail quota?
Lot size: 25 shares. The retail investor quota is at least 35%.
6. Is the Sudeep Pharma IPO mostly fresh issue or OFS?
It is heavily skewed towards OFS (~₹ 800 crore) with only ~₹ 95 crore as fresh issue.
7. What are the main uses of proceeds from the fresh issue?
Majority (~₹ 75.81 crore) for machinery capex at Nandesari Facility I; the balance for general corporate purposes.
8. What are the major risks for investors?
Key risks include customer concentration, regional manufacturing concentration, regulatory/compliance risks around ingredients, and the high OFS component reducing fresh growth capital.
9. What growth has the company shown recently?
Revenue grew from ~₹ 428.74 cr in FY 23 to ~₹ 511.33 cr in FY 25; PAT grew from ~₹ 62.32 cr in FY 23 to ~₹ 138.69 cr in FY 25.
10. How do I apply for the Sudeep Pharma IPO?
You can apply using ASBA via your bank or through your trading platform/broker when the IPO is open (21-25 Nov 2025). Ensure you have requisite margin blocked before bidding.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
